scholarly journals Pre-Transplant Ferritin, Albumin and Hemoglobin Are Predictive Biomarkers of Survival Outcome Adding Prognostic Value to Disease Risk Index Following Allogeneic Stem Cell Transplantation

2016 ◽  
Vol 22 (3) ◽  
pp. S308-S309
Author(s):  
Lynette Chui Yen Chee ◽  
Mark Tacey ◽  
Bernice Lim ◽  
Andrew Boon Ming Lim ◽  
Jeffrey Szer ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Allogeneic Stem Cell Transplantation ◽  
Prognostic Value ◽  
Disease Risk ◽  
Risk Index ◽  
Predictive Biomarkers ◽  
Survival Outcome

scholarly journals Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation

Blood ◽  
2014 ◽  
Vol 123 (23) ◽  
pp. 3664-3671 ◽  
Author(s):  
Philippe Armand ◽  
Haesook T. Kim ◽  
Brent R. Logan ◽  
Zhiwei Wang ◽  
Edwin P. Alyea ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Allogeneic Stem Cell Transplantation ◽  
Disease Risk ◽  
Risk Index ◽  
Allogeneic Transplantation ◽  
Key Points ◽  
Conditioning Intensity

Key Points The DRI successfully stratified patients in a very large allogeneic transplantation registry cohort. The DRI was refined by using this cohort to build a more inclusive and conditioning intensity–independent index.

Validating the Allogeneic Stem Cell Transplantation Disease Risk Index

2015 ◽  
Vol 99 (1) ◽  
pp. 128-132 ◽  
Author(s):  
Andrew B.M. Lim ◽  
Andrew W. Roberts ◽  
Kate Mason ◽  
Ashish Bajel ◽  
Jeff Szer ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Allogeneic Stem Cell Transplantation ◽  
Disease Risk ◽  
Risk Index

scholarly journals A novel Iowa–Mayo validated composite risk assessment tool for allogeneic stem cell transplantation survival outcome prediction

2021 ◽  
Vol 11 (11) ◽  
Author(s):  
Kalyan Nadiminti ◽  
Kimberly Langer ◽  
Ehsan Shabbir ◽  
Mehrdad Hefazi ◽  
Lindsay Dozeman ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Cox Regression ◽  
Disease Risk ◽  
Risk Index ◽  
Disease Free Survival ◽  
Donor Age ◽  
Hematopoietic Stem ◽  
Cmv Status

AbstractAllogeneic hematopoietic stem cell transplantation (HSCT) is a curative option for many hematologic conditions and is associated with considerable morbidity and mortality. Therefore, prognostic tools are essential to navigate the complex patient, disease, donor, and transplant characteristics that differentially influence outcomes. We developed a novel, comprehensive composite prognostic tool. Using a lasso-penalized Cox regression model (n = 273), performance status, HCT-CI, refined disease-risk index (rDRI), donor and recipient CMV status, and donor age were identified as predictors of disease-free survival (DFS). The results for overall survival (OS) were similar except for recipient CMV status not being included in the model. Models were validated in an external dataset (n = 378) and resulted in a c-statistic of 0.61 and 0.62 for DFS and OS, respectively. Importantly, this tool incorporates donor age as a variable, which has an important role in HSCT outcomes. This needs to be further studied in prospective models. An easy-to-use and a web-based nomogram can be accessed here: https://allohsctsurvivalcalc.iowa.uiowa.edu/.

scholarly journals MRD Tailored Therapy in AML: What We Have Learned So Far

2021 ◽  
Vol 10 ◽  
Author(s):  
Lok Lam Ngai ◽  
Angèle Kelder ◽  
Jeroen J. W. M. Janssen ◽  
Gert J. Ossenkoppele ◽  
Jacqueline Cloos
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Allogeneic Stem Cell Transplantation ◽  
Prognostic Value ◽  
Residual Disease ◽  
Surrogate Endpoint ◽  
Multiparameter Flow Cytometry ◽  
Clinical Aspects ◽  
Intensive Chemotherapy

Acute myeloid leukemia (AML) is a heterogeneous clonal disease associated with a dismal survival, partly due to the frequent occurrence of relapse. Many patient- and leukemia-specific characteristics, such as age, cytogenetics, mutations, and measurable residual disease (MRD) after intensive chemotherapy, have shown to be valuable prognostic factors. MRD has become a rich field of research where many advances have been made regarding technical, biological, and clinical aspects, which will be the topic of this review. Since many laboratories involved in AML diagnostics have experience in immunophenotyping, multiparameter flow cytometry (MFC) based MRD is currently the most commonly used method. Although molecular, quantitative PCR based techniques may be more sensitive, their disadvantage is that they can only be applied in a subset of patients harboring the genetic aberration. Next-generation sequencing can assess and quantify mutations in many genes but currently does not offer highly sensitive MRD measurements on a routine basis. In order to provide reliable MRD results, MRD assay optimization and standardization is essential. Different techniques for MRD assessment are being evaluated, and combinations of the methods have shown promising results for improving its prognostic value. In this regard, the load of leukemic stem cells (LSC) has also been shown to add to the prognostic value of MFC-MRD. At this moment, MRD after intensive chemotherapy is most often used as a prognostic factor to help stratify patients, but also to select the most appropriate consolidation therapy. For example, to guide post-remission treatment for intermediate-risk patients where MRD positive patients receive allogeneic stem cell transplantation and MRD negative receive autologous stem cell transplantation. Other upcoming uses of MRD that are being investigated include: selecting the type of allogeneic stem cell transplantation therapy (donor, conditioning), monitoring after stem cell transplantation (to allow intervention), and determining drug efficacy for the use of a surrogate endpoint in clinical trials.

Sign in / Sign up

Export Citation Format

Share Document